Product Information
Registration Status: ActiveSIN11223P
INTEGRILIN IV BOLUS INJECTION 2mg/ML is approved to be sold in Singapore with effective from 1999-11-11. It is marketed by MSD PHARMA (SINGAPORE) PTE LTD, with the registration number of SIN11223P.
This product contains Eptifibatide 2mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by Patheon Italia in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.
Indication
For treatment of myocardial infarction and acute coronary syndrome.
Mechanism of Action
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.
Clearance
* 55 mL/kg/h [patients with coronary artery disease]
Toxicity
Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)
Active Ingredient/Synonyms
Integrelin | Intrifiban | Eptifibatide |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.